Docosahexaenoic acid supplementation in preterm neonates admitted in NICUand its effect on inflammatory markers at Day 10
Phase 3
- Conditions
- Health Condition 1: P84- Other problems with newborn
- Registration Number
- CTRI/2023/06/053850
- Lead Sponsor
- Saiteja
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Early preterm neonates (32-34 weeks) delivered at RL Jalappa Hospital whose parents had consented to be a part in the study.
- Clincally stable neonates to begin enteral feeding
Exclusion Criteria
Neonates with congenital anomalies
-Neonates born to Mothers with PPROM history
-Neonates with contraindication for enteral feeding
-Neonates with maternal use of omega-3 supplements
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To measure the inflammatory markers at day 10 of admission in babies with DHA supplementation <br/ ><br>To measure the inflammatory markers at day 10 of admission in babies without supplementation of DHA <br/ ><br>To compare the level of inflammatory markers between two groups <br/ ><br>Timepoint: Day 10 of life <br/ ><br>
- Secondary Outcome Measures
Name Time Method To compare the defined clinical outcomes i.e (sepsis, necrotising enterocolitis, bronchopulmonary dysplasia,and retinopathy of prematurity )Timepoint: Hospital admission to discharge